These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

51 related items for PubMed ID: 1301801

  • 1. Inhibition of vincristine-induced retinal impairments by a specific PAF antagonist.
    Doly M, Millerin M, Bonhomme B, Droy-Lefaix MT, Braquet P.
    Lens Eye Toxic Res; 1992; 9(3-4):529-35. PubMed ID: 1301801
    [Abstract] [Full Text] [Related]

  • 2. Protective effect of a specific PAF antagonist on vincristine-induced experimental retinopathy.
    Doly M, Cluzel J, Bonhomme B, Millerin M, Braquet P.
    Acta Ophthalmol Scand; 1995 Apr; 73(2):155-7. PubMed ID: 7656145
    [Abstract] [Full Text] [Related]

  • 3. [Involvement of PAF (Platelet-Activating Factor) in chloroquine-induced retinopathy].
    Meyniel G, Doly M, Millerin M, Braquet P.
    C R Acad Sci III; 1992 Apr; 314(2):61-5. PubMed ID: 1559183
    [Abstract] [Full Text] [Related]

  • 4. Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730.
    Doly M, Cluzel J, Millerin M, Bonhomme B, Braquet P.
    Ophthalmic Res; 1993 Apr; 25(5):314-8. PubMed ID: 8259265
    [Abstract] [Full Text] [Related]

  • 5. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
    Akagi M, Nishioka E, Kanoh R, Tachibana M, Fukuishi N.
    Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
    [Abstract] [Full Text] [Related]

  • 6. Platelet-activating factor in vasoobliteration of oxygen-induced retinopathy.
    Beauchamp MH, Marrache AM, Hou X, Gobeil F, Bernier SG, Lachapelle P, Abran D, Quiniou C, Brault S, Peri KG, Roberts J, Almazan G, Varma DR, Chemtob S.
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3327-37. PubMed ID: 12356842
    [Abstract] [Full Text] [Related]

  • 7. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [Abstract] [Full Text] [Related]

  • 9. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
    Rabinovici R, Yue TL, Farhat M, Smith EF, Esser KM, Slivjak M, Feuerstein G.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):256-63. PubMed ID: 2213560
    [Abstract] [Full Text] [Related]

  • 10. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
    Yue TL, Rabinovici R, Farhat M, Feuerstein G.
    J Lipid Mediat; 1991 Oct; 3(1):13-26. PubMed ID: 1768837
    [Abstract] [Full Text] [Related]

  • 11. [Suppression of platelet activating factor effects (PAF) on the retina by G-proteins inhibitors].
    Doly M, Oustrin J.
    Ann Pharm Fr; 1996 Oct; 54(2):64-7. PubMed ID: 8734330
    [Abstract] [Full Text] [Related]

  • 12. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
    Yue TL, Gleason MM, Gu JL, Lysko PG, Hallenbeck J, Feuerstein G.
    J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
    [Abstract] [Full Text] [Related]

  • 13. Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat.
    Dyson MC, Bellan JA, Minkes RK, Beckerman RC, Wegmann MJ, Braquet P, McNamara DB, Kadowitz PJ.
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1320-7. PubMed ID: 2175802
    [Abstract] [Full Text] [Related]

  • 14. Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility.
    Delbridge LM, Stewart AG, Goulter CM, Morgan TO, Harris PJ.
    J Mol Cell Cardiol; 1994 Feb; 26(2):185-93. PubMed ID: 8006979
    [Abstract] [Full Text] [Related]

  • 15. Basal and PAF-, interleukin 1-, ether stress-induced hypothalamic pituitary adrenal secretion of conscious rat: modulation by PAF antagonists.
    Rougeot C, Tiberghein C, Minary P, Dray F.
    J Lipid Mediat; 1991 Feb; 4(1):45-59. PubMed ID: 1654152
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
    Casals-Stenzel J, Muacevic G, Weber KH.
    J Pharmacol Exp Ther; 1987 Jun; 241(3):974-81. PubMed ID: 3598913
    [Abstract] [Full Text] [Related]

  • 17. Involvement of platelet activating factor in immediate heart response to lipopolysaccharide.
    Jakubowski A, Olszanecki R, Chlopicki S.
    J Physiol Pharmacol; 2004 Jun; 55(2):409-21. PubMed ID: 15213362
    [Abstract] [Full Text] [Related]

  • 18. Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits.
    Yue TL, Farhat M, Rabinovici R, Perera PY, Vogel SN, Feuerstein G.
    J Pharmacol Exp Ther; 1990 Sep; 254(3):976-81. PubMed ID: 2395125
    [Abstract] [Full Text] [Related]

  • 19. Platelet-activating factor is a messenger in the electroconvulsive shock-induced transcriptional activation of c-fos and zif-268 in hippocampus.
    Marcheselli VL, Bazan NG.
    J Neurosci Res; 1994 Jan; 37(1):54-61. PubMed ID: 8145303
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086.
    Wilson DV, Eberhart SW, Robinson NE, Rice R, Gray PR.
    Am J Vet Res; 1993 Feb; 54(2):274-9. PubMed ID: 8430938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.